The Madras High Court clarified the interpretation of Section 3c regarding patent eligibility of monoclonal antibodies in India. The Court held that synthetic antibodies may be patentable if they demonstrate novelty or technical advancement.
Read more about Monoclonal antibodies and Patents – How the Madras High Court interpreted Section 3(c)